tdo2b Antibody

What is TDO2 and why is it important in cancer research?

TDO2 (Tryptophan 2,3-Dioxygenase) is an enzyme involved in the catabolism of tryptophan that plays a crucial role in regulating immune responses through the kynurenine pathway. TDO2 has gained significance in cancer research because it facilitates immune evasion by tumors through creating immunosuppressive environments. The enzyme mediates the first and rate-limiting step of the kynurenine pathway, converting tryptophan into N-formylkynurenine . This process results in tryptophan depletion and kynurenine accumulation in the tumor microenvironment, which suppresses anti-tumor immunity by inhibiting T cell proliferation/activation and promoting differentiation of monocytes into immunosuppressive tumor-associated macrophages . Recent research has demonstrated that TDO2 is highly expressed in various cancer types, including cutaneous squamous cell carcinoma (cSCC), making it a promising target for cancer immunotherapy .

What applications are TDO2 antibodies used for in experimental research?

TDO2 antibodies are utilized in multiple experimental applications across cancer research, immunology, and neurobiology. The primary applications include:

• Western Blotting (WB) - For detecting and quantifying TDO2 protein expression in cell or tissue lysates

• Immunohistochemistry (IHC) - Both for paraffin-embedded and frozen tissue sections to visualize TDO2 expression patterns

• Immunoprecipitation (IP) - To isolate and concentrate TDO2 from complex protein mixtures

• Immunocytochemistry (ICC) - To determine subcellular localization of TDO2

• ELISA - For quantitative measurement of TDO2 in solution

• In situ hybridization - Often used alongside immunofluorescence to validate cellular localization

These methods have been instrumental in discovering that TDO2 is predominantly expressed in cancer-associated fibroblasts (CAFs) in certain tumors, such as cSCC, where its expression significantly exceeds that in fibroblasts from sun-exposed skin tissues .

What are the key differences between monoclonal and polyclonal TDO2 antibodies?

When selecting TDO2 antibodies for research, understanding the differences between monoclonal and polyclonal options is essential:

For research requiring precise epitope recognition, such as studying specific functional domains of TDO2, monoclonal antibodies are preferable. For detecting TDO2 across various species or in applications where signal strength is important, polyclonal antibodies may be more suitable .

How should TDO2 antibodies be stored and handled to maintain optimal activity?

Proper storage and handling of TDO2 antibodies are essential for maintaining their activity and specificity:

• Storage temperature: Most TDO2 antibodies should be stored at -20°C for long-term preservation or at 4°C for short-term use

• Buffer conditions: Typically maintained in PBS (pH 7.3) with stabilizing proteins

• Aliquoting: For antibodies used frequently, create small aliquots to avoid repeated freeze-thaw cycles which can degrade antibody performance

• Working dilutions: Prepare fresh working dilutions on the day of the experiment

• Avoid contamination: Use sterile technique when handling antibodies

• Transportation: Ship with cold packs or on dry ice for longer journeys

• Concentration: Most commercial TDO2 antibodies come in liquid format with lot-specific concentrations, so check documentation for specific handling recommendations

Following these guidelines will help ensure consistent experimental results when using TDO2 antibodies for various applications.

How does TDO2 expression in cancer-associated fibroblasts affect tumor microenvironment and immune cell infiltration?

Recent single-cell RNA sequencing studies have revealed that TDO2 is significantly upregulated in cancer-associated fibroblasts (CAFs) within cutaneous squamous cell carcinoma (cSCC). This upregulation has profound effects on the tumor microenvironment and immune cell infiltration:

• Immune cell infiltration: High TDO2 expression in CAFs correlates with reduced CD8+ T cell infiltration in tumor tissues. Quantitative immunohistochemistry analysis has demonstrated a significant negative correlation between the presence of TDO2+ cells and CD8+ T cells in cSCC samples .

• Tumor differentiation: Clinical correlation analyses have shown that high TDO2 expression is significantly associated with poor tumor differentiation. Statistical assessment of 30 cSCC patients revealed that highly differentiated tumors were more frequently associated with elevated CD8+ T cell levels, while medium-low differentiated tumors showed lower CD8+ T cell infiltration .

• Immune evasion mechanism: TDO2+ CAFs induce immune evasion specifically by inhibiting CD8+ T cell infiltration, creating an immunosuppressive microenvironment that protects tumor cells from immune surveillance .

The relationship between TDO2 expression, tumor differentiation, and CD8+ T cell infiltration is summarized in the following table:

This data demonstrates that TDO2 expression in CAFs contributes to an immunosuppressive microenvironment that favors tumor progression by limiting cytotoxic T cell infiltration .

What are the methodological considerations for using TDO2 antibodies in multiplex immunohistochemistry?

When implementing multiplex immunohistochemistry (mIHC) with TDO2 antibodies for studying complex cellular interactions in the tumor microenvironment, several methodological considerations must be addressed:

• Antibody panel design:

  • Carefully select antibodies that don't cross-react and can be used with compatible fluorophores

  • For studying TDO2+ CAFs and immune interactions, combine TDO2 with markers like α-SMA (for CAFs), CD8 (for cytotoxic T cells), CD4 (for helper T cells), FOXP3 (for regulatory T cells), and CD206 (for M2 macrophages)

• Epitope retrieval and antibody stripping:

  • Use optimized antigen retrieval methods that preserve tissue integrity

  • For multi-round staining, ensure complete antibody stripping between rounds

  • Validate that sequential staining doesn't compromise TDO2 epitope detection

• Signal amplification and visualization:

  • Use tyramide signal amplification (TSA) for detecting low-abundance targets

  • Employ spectral unmixing to resolve overlapping fluorescence signals

  • Include proper controls for autofluorescence subtraction, particularly important in skin specimens

• Image acquisition and analysis:

  • Use serial sectioning techniques for comparative analyses

  • Implement quantitative image analysis for measuring spatial relationships between TDO2+ cells and immune cell populations

  • Apply appropriate statistical methods for correlation analyses, such as those used to determine the negative correlation between TDO2+ cells and CD8+ T cells

Successful implementation of these methodological approaches has enabled researchers to demonstrate that regions with high TDO2 expression have reduced numbers of CD8+ cytotoxic T lymphocytes, while regions with lower TDO2 expression exhibit higher densities of these cells .

How can TDO2 antibodies be used to evaluate the efficacy of TDO2 inhibitors in preclinical models?

TDO2 antibodies serve as crucial tools for evaluating the efficacy of TDO2 inhibitors in preclinical cancer models. An effective methodological approach includes:

• Target engagement assessment:

  • Use TDO2 antibodies in Western blotting and immunohistochemistry to confirm presence and quantity of the target protein

  • Combine with enzymatic assays to correlate protein levels with functional enzyme activity

• Pharmacodynamic biomarker evaluation:

  • Employ TDO2 antibodies in tissue samples before and after treatment to assess changes in protein expression

  • Correlate with measurements of kynurenine/tryptophan ratios in serum and tumor tissue

• Tumor microenvironment analysis:

  • Use multiplex immunofluorescence with TDO2 antibodies alongside immune cell markers (CD8, CD4, FOXP3, CD206) to track changes in the immune landscape

  • Quantify changes in immune cell infiltration patterns after TDO2 inhibitor treatment

• Downstream signaling pathway assessment:

  • Combine TDO2 immunodetection with phospho-specific antibodies to evaluate effects on key pathways like PI3K-Akt

  • Research has shown that TDO2 inhibitors significantly decrease phosphorylated PI3K and AKT levels in treated tumors

Recent preclinical studies using these approaches demonstrated that TDO2 inhibitors significantly reduced tumor size and number in mouse models and effectively increased CD8+ T cell infiltration. RNA sequencing and subsequent pathway analyses revealed that TDO2 inhibitors modulate immune cell activity and downregulate the PI3K-Akt signaling pathway, providing mechanistic insights into their anti-tumor effects .

What is the relationship between TDO2 and synthetic essentiality in APC-deficient colorectal cancer?

Research into synthetic essentiality (SE) has identified TDO2 as a key downstream effector specifically in APC-deficient colorectal cancer (CRC). This finding has important implications for targeted therapy development:

• Synthetic essentiality concept:

  • Synthetic essentiality refers to genes that become essential for survival specifically in cells with certain mutations

  • In APC-deficient CRC, TDO2 appears to become synthetically essential, making it a potential therapeutic target with reduced side effects on normal cells

• Mechanistic relationship:

  • TDO2 mediates the first and rate-limiting step of the kynurenine pathway, converting tryptophan into N-formylkynurenine

  • In APC-deficient contexts, this metabolic pathway becomes critical for tumor survival and immune evasion

  • TDO2 is highly expressed and constitutively active in these cancers, resulting in kynurenine accumulation in the tumor microenvironment

• Dual effects on tumor biology:

  • Immune suppression: Tryptophan depletion and kynurenine accumulation promote differentiation of monocytes into immunosuppressive tumor-associated macrophages and inhibit T cell proliferation/activation

  • Cell-intrinsic mechanisms: Kynurenine acts as an agonist for aryl hydrocarbon receptor (AhR), which upregulates pro-tumorigenic genes

TDO2 antibodies are essential tools for investigating this synthetic essentiality relationship, enabling researchers to verify TDO2 expression levels in patient samples and experimental models, and to evaluate the efficacy of targeted interventions against this pathway in APC-deficient contexts.

What are the optimal conditions for using TDO2 antibodies in Western blotting for cancer research?

For optimal Western blotting results with TDO2 antibodies in cancer research, consider these technical parameters:

• Sample preparation:

  • Extract proteins using RIPA buffer supplemented with protease inhibitors

  • For tumor samples, use homogenization techniques that preserve protein integrity

  • Quantify protein concentration and standardize loading (typically 20-50 μg total protein)

• Gel electrophoresis and transfer conditions:

  • Use 10-12% SDS-PAGE gels for optimal resolution of TDO2 (~48 kDa)

  • Transfer to PVDF membranes (preferred over nitrocellulose for TDO2)

  • Transfer at 100V for 60-90 minutes using cold transfer buffer with 20% methanol

• Antibody incubation parameters:

  • Blocking: 5% non-fat dry milk in TBST for 1 hour at room temperature

  • Primary antibody: Dilute TDO2 antibody as per manufacturer recommendations (typically 1:500-1:2000) in blocking solution

  • Incubation: Overnight at 4°C with gentle rocking

  • Secondary antibody: HRP-conjugated antibody at 1:5000-1:10000 for 1 hour at room temperature

• Detection and quantification:

  • Use enhanced chemiluminescence (ECL) detection systems

  • For comparison between tumor and normal tissues, include β-actin or GAPDH as loading controls

  • For quantification, use digital imaging systems and normalize TDO2 signal to loading controls

These optimized conditions have been successfully used to demonstrate differential TDO2 expression between tumor and normal tissues, as well as to evaluate the effects of TDO2 inhibitors on signaling pathways like PI3K-Akt in experimental models .

How can researchers effectively validate TDO2 antibody specificity for their experimental systems?

Thorough validation of TDO2 antibody specificity is crucial to ensure reliable experimental results. A comprehensive validation approach includes:

• Positive and negative controls:

  • Positive controls: Tissues known to express TDO2 (liver samples are excellent positive controls)

  • Negative controls: Use tissues from TDO2 knockout models or cells with CRISPR-mediated TDO2 deletion

  • Competitive inhibition: Pre-incubate antibody with recombinant TDO2 protein before application to demonstrate binding specificity

• Multiple detection methods:

  • Cross-validate findings using different antibody clones targeting distinct epitopes

  • Compare results from antibodies produced in different host species

  • Correlate protein detection with mRNA expression (using RT-PCR or RNA-seq)

  • Confirm findings using both monoclonal and polyclonal antibodies when possible

• Epitope-specific validation:

  • For antibodies targeting specific regions (N-term vs. full-length), compare their performance in detecting different isoforms

  • Consider using epitope-tagged recombinant TDO2 as additional controls

  • Test antibodies against peptide arrays to confirm epitope specificity

• Cross-reactivity assessment:

  • Test against related enzymes (especially IDO1 and IDO2, which have similar functions)

  • When working across species, validate the antibody in each target species

  • Perform immunoprecipitation followed by mass spectrometry to confirm antibody captures the intended target

These validation approaches have been essential in studies that identified TDO2 expression specifically in cancer-associated fibroblasts within cutaneous squamous cell carcinoma, where meticulous validation ensured accurate cellular localization of TDO2 .

What methodologies can be used to study the relationship between TDO2 expression and immune cell function in the tumor microenvironment?

Investigating the relationship between TDO2 expression and immune cell function requires a multi-faceted methodological approach:

• Spatial analysis of the tumor microenvironment:

  • Multiplex immunohistochemistry (mIHC) to simultaneously visualize TDO2+ cells and immune cell populations

  • Serial sectioning and immunostaining for TDO2, CD8, CD4, FOXP3, and CD206 to map spatial relationships

  • Digital pathology and quantitative image analysis to measure distances between TDO2+ cells and immune cells

• Functional immune cell assays:

  • Isolate tumor-infiltrating lymphocytes (TILs) from regions with high vs. low TDO2 expression

  • Assess T cell proliferation, cytokine production, and cytotoxicity in the presence of TDO2+ CAFs

  • Use transwell co-culture systems to evaluate immune cell migration in response to TDO2+ cells

• Mechanistic studies:

  • Measure kynurenine/tryptophan ratios in the tumor microenvironment using HPLC or mass spectrometry

  • Evaluate downstream signaling in immune cells using phospho-flow cytometry

  • Study gene expression changes in immune cells exposed to conditioned media from TDO2+ CAFs

• In vivo manipulation:

  • Use selective TDO2 inhibitors in animal models to assess changes in immune cell infiltration and function

  • Implement adoptive transfer of labeled immune cells to track their fate in tumors with high TDO2 expression

  • Apply RNA sequencing to analyze transcriptional changes in both tumor and immune cells following TDO2 inhibition

Research using these methodologies has revealed that TDO2 inhibitors significantly increase CD8+ T cell infiltration in tumors and modulate immune cell activity through multiple molecular mechanisms, particularly by regulating the PI3K-Akt signaling pathway. This offers important insights for developing immunotherapeutic strategies targeting the TDO2 pathway .

How does antibody selection impact bioprocess optimization for therapeutic antibody production?

When optimizing bioprocesses for therapeutic antibody production, including potential TDO2-targeting antibodies, several key factors must be considered:

• Cell line development and screening:

  • Use TDO2 antibodies to screen and select high-producing clones

  • Apply immunoassays to assess antibody quality and target binding during clone selection

  • Implement high-throughput screening methods to identify optimal production conditions

• Feed optimization strategies:

  • Hybrid semi-parametric models can be used to perform in silico experimental campaigns

  • Design of Experiments-Driven Evolution (DoDE) methodologies provide efficient optimization frameworks

  • When properly implemented, these approaches can significantly increase antibody titers (up to 34.9% in some studies)

• Analytical method development:

  • Develop robust immunoassays using reference TDO2 antibodies for product characterization

  • Implement in-process analytics to monitor critical quality attributes throughout production

  • Validate assay performance across different production scales

• Process monitoring and control:

  • Use near real-time analytics to adjust feeding schedules based on culture performance

  • Monitor nutrient profiles to maintain optimal conditions for antibody production

  • Compare experimental outcomes with model predictions to refine optimization strategies

Recent studies have demonstrated that optimized feeding schedules can achieve antibody titers as high as 3,222.8 mg/L, approaching the theoretical process optimum of 3,228.8 mg/L. This represents significant improvements over conventional approaches, with some optimized strategies achieving higher yields in just nine experiments compared to traditional methods requiring 31 experiments .

What are common troubleshooting strategies for inconsistent TDO2 antibody staining in immunohistochemistry?

When encountering inconsistent TDO2 antibody staining in immunohistochemistry, consider these systematic troubleshooting approaches:

• Tissue processing and fixation issues:

  • Problem: Overfixation in formalin can mask TDO2 epitopes

  • Solution: Optimize fixation time (24 hours maximum) or use antigen retrieval methods specific for TDO2 (typically citrate buffer pH 6.0 or EDTA buffer pH 9.0)

  • Validation: Test different antigen retrieval methods on sequential sections from the same block

• Antibody-specific considerations:

  • Problem: Batch-to-batch variability, especially with polyclonal antibodies

  • Solution: Titrate each new antibody lot and include reference positive controls

  • Validation: Compare staining patterns between different antibody clones targeting the same or different TDO2 epitopes

• Cell type-specific expression patterns:

  • Problem: Misinterpretation of TDO2 staining due to unknown cell type specificity

  • Solution: Use multiplex staining with cell-type markers (e.g., α-SMA for fibroblasts)

  • Validation: Confirm cellular co-localization with in situ hybridization for TDO2 mRNA

• Technical considerations:

  • Problem: Background staining or weak signal

  • Solution: Modify blocking conditions (increase to 5-10% serum or BSA) and optimize antibody concentrations

  • Validation: Include isotype controls and secondary-only controls to assess non-specific binding

Studies investigating TDO2 expression in cancer-associated fibroblasts have successfully addressed these challenges by implementing a multi-modal validation approach, combining immunofluorescence with in situ hybridization to confirm TDO2 localization within α-SMA-positive CAFs in cutaneous squamous cell carcinoma tissues .

How can researchers integrate TDO2 antibody-based detection with RNA sequencing data to better understand its role in tumor biology?

Integrating TDO2 antibody-based protein detection with RNA sequencing data provides a powerful approach for comprehensive understanding of TDO2's role in tumor biology:

• Correlation of protein and transcript levels:

  • Use TDO2 antibodies for immunohistochemistry or Western blotting on samples paralleling those used for RNA-seq

  • Implement spatial transcriptomics alongside protein staining to correlate spatial expression patterns

  • Analyze concordance and discordance between protein and mRNA expression to identify post-transcriptional regulation

• Single-cell multi-omics approaches:

  • Combine single-cell RNA sequencing with antibody-based protein detection (e.g., CITE-seq)

  • Use computational methods to integrate protein and transcript data at single-cell resolution

  • Identify cell populations with discrepancies between TDO2 protein and mRNA expression

• Functional validation of RNA-seq findings:

  • Use RNA-seq to identify pathways associated with TDO2 expression (like PI3K-Akt signaling)

  • Validate pathway activation using antibodies against phosphorylated proteins in these pathways

  • Perform perturbation experiments with TDO2 inhibitors and measure effects on both transcriptome and proteome

• Mechanistic insights from integrative analysis:

  • Analyze transcriptional changes in immune cells within TDO2-rich regions

  • Correlate gene expression signatures with spatial protein expression patterns

  • Identify transcription factors regulating TDO2 expression in specific cell types

This integrative approach has been successfully applied in studies of cutaneous squamous cell carcinoma, where RNA sequencing analysis of tissues treated with TDO2 inhibitors revealed modulation of immune cell activity and downregulation of the PI3K-Akt signaling pathway, providing mechanistic insights into how TDO2 inhibition enhances anti-tumor immune responses .

What are the considerations for developing sandwich ELISA assays for quantitative measurement of TDO2 in biological samples?

Developing a sensitive and specific sandwich ELISA for TDO2 quantification requires careful consideration of multiple technical aspects:

• Antibody pair selection:

  • Choose capture and detection antibodies recognizing non-overlapping epitopes

  • Test combinations of monoclonal antibodies or use a monoclonal-polyclonal pair

  • Validate that the selected pair does not interfere with each other's binding

  • Consider using antibodies targeting different regions (e.g., N-terminal and C-terminal)

• Assay optimization parameters:

  • Coating buffer: Test carbonate buffer (pH 9.6) vs. PBS (pH 7.4) for optimal capture antibody binding

  • Blocking agents: Compare BSA, casein, and commercial blockers for lowest background

  • Incubation conditions: Optimize temperature and duration for antigen capture (typically 2-4 hours at room temperature or overnight at 4°C)

  • Detection system: Compare HRP, AP, or fluorescent detection for optimal sensitivity and dynamic range

• Sample preparation considerations:

  • For serum/plasma: Determine optimal dilution factor to minimize matrix effects

  • For tissue samples: Optimize extraction buffers to maintain TDO2 stability and solubility

  • For cell culture supernatants: Consider concentration steps for low-abundance samples

• Standard curve and quality control:

  • Use recombinant TDO2 protein as standard (preferably from the same species as samples)

  • Include internal quality controls at low, medium, and high concentrations

  • Determine assay performance characteristics: LLOD, LLOQ, intra- and inter-assay CV%

  • Validate spike-recovery and parallelism to confirm accuracy across sample types

This methodical approach to ELISA development enables accurate quantification of TDO2 in various biological samples, facilitating research into its role in cancer progression and response to therapeutic interventions.

How can researchers integrate TDO2 inhibition studies with antibody-based detection to develop targeted cancer immunotherapies?

Integrating TDO2 inhibition studies with antibody-based detection methods creates a powerful framework for developing targeted cancer immunotherapies:

• Target validation and patient stratification:

  • Use TDO2 antibodies to screen patient tumor samples for expression levels

  • Correlate TDO2 expression with immune infiltration patterns and clinical outcomes

  • Identify patient subgroups most likely to benefit from TDO2 inhibition based on expression profiles

• Pharmacodynamic biomarker development:

  • Apply immunohistochemistry with TDO2 antibodies to assess target engagement

  • Develop companion diagnostic assays to monitor treatment response

  • Combine with metabolomic analyses of kynurenine pathway metabolites

• Combinatorial therapy assessment:

  • Use multiplexed antibody staining to evaluate changes in the tumor immune landscape during TDO2 inhibition

  • Analyze synergistic effects with other immunotherapies (e.g., checkpoint inhibitors)

  • Monitor changes in PI3K-Akt pathway activation and other downstream signaling events

• Translational research workflow:

  • Preclinical phase: Use TDO2 antibodies to confirm target expression in xenograft models

  • Early clinical development: Implement immunohistochemistry in patient biopsies for dose-finding studies

  • Biomarker implementation: Develop standardized TDO2 IHC protocols for routine clinical use

This integrated approach has shown promise in cutaneous squamous cell carcinoma research, where TDO2 inhibitors were found to enhance CD8+ T cell infiltration and suppress tumor progression. RNA sequencing and pathway analyses further revealed that TDO2 inhibitors modulate immune cell function through multiple molecular mechanisms, particularly by enhancing the cytotoxic function of CD8+ T cells. These findings provide important scientific evidence for the development of new therapeutic approaches targeting the TDO2 pathway in cancer treatment .